Literature DB >> 18090906

Patterns and trends of pancreatic cancer mortality rates in Arkansas, 1969-2002: a comparison with the US population.

Jianjun Zhang1, Ishwori Dhakal, Baitang Ning, Hugo Kesteloot.   

Abstract

Little is known about trends in pancreatic cancer mortality in individual states of the US and its whole population. This study aimed to describe the patterns and trends of pancreatic cancer mortality in Arkansas, 1969-2002, using the US national rates as a reference. Joinpoint regression analyses were performed to evaluate trends in age-standardized mortality rates of pancreatic cancer by age group, sex, and race, using data obtained from the National Center for Health Statistics. Throughout the period examined, mortality decreased in young and middle-aged people (<60 years) and men but increased in old people (>/=60 years) and women. A continuous fall in mortality occurred among whites except for a transient rise in the late 1970s. For blacks, mortality rates did not cease to increase until 1995. Unlike in Arkansas, a monotonic upward or downward trend in mortality by age group and sex was not observed in the US. A decline of mortality stopped in 1997 for US whites. Recent decreasing trends were more pronounced in Arkansas blacks than in US blacks. Changes of pancreatic cancer mortality in the last three decades in Arkansas remarkably differed by age, sex, and race and were different in patterns from those of the US population.

Entities:  

Mesh:

Year:  2008        PMID: 18090906     DOI: 10.1097/CEJ.0b013e32809b4ccd

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  9 in total

Review 1.  Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.

Authors:  Fnu Asad Ur Rahman; Saeed Ali; Muhammad Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2017-04-26       Impact factor: 4.409

2.  National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010.

Authors:  Yun Wang; Deborah Schrag; Gabriel A Brooks; Francesca Dominici
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

3.  From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2021-05-31

4.  The accuracy of sentinel node biopsy by 99mTc-sodium phytate in patients with pancreatic cancer.

Authors:  Ramin Sadeghi; Mohsen Aliakbarian; Hamed Shayegani; Bahram Memar; Vahid Reza Dabbagh
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-08-31

5.  Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.

Authors:  Senem Karabulut; Çiğdem Usul Afsar; Mehmet Karabulut; Halil Alış; Leyla Kılıc; Murat Çikot; Ceren Tilgen Yasasever; Nuri Faruk Aykan
Journal:  J Gastrointest Cancer       Date:  2016-03

6.  Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.

Authors:  Ioannis Pozios; Thomas Knösel; Yue Zhao; Gerald Assmann; Iraklis Pozios; Mario H Müller; Christiane J Bruns; Martin E Kreis; Hendrik Seeliger
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-25       Impact factor: 4.553

Review 7.  Genetic factors affecting patient responses to pancreatic cancer treatment.

Authors:  George Fotopoulos; Konstantinos Syrigos; Muhammad Wasif Saif
Journal:  Ann Gastroenterol       Date:  2016-06-10

8.  The impact of a history of cancer on pancreatic ductal adenocarcinoma survival.

Authors:  Xingkang He; Yue Li; Tingting Su; Sanchuan Lai; Wenrui Wu; Luyi Chen; Jianmin Si; Leimin Sun
Journal:  United European Gastroenterol J       Date:  2018-04-30       Impact factor: 4.623

9.  Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma.

Authors:  Ralph F Staerkle; Raphael Nicolas Vuille-Dit-Bille; Christopher Soll; Rebekka Troller; Jaswinder Samra; Milo A Puhan; Stefan Breitenstein
Journal:  Cochrane Database Syst Rev       Date:  2021-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.